An Early Phase 1 interventional study of Triamcinolone and Vitamin D3 in Plaque Psoriasis and Vitamin D3, sponsored by Wright State University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-19.
Sponsored by Wright State University · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 766 studies in Psoriasis with a site in United States — 57 open to participants now, 88 under way, 19 of them phase 3. Psoriasis · United States.
Among the 766 studies in Psoriasis with a site in United States, this one is the 522nd largest by planned enrollment of the 675 interventional ones that give a count, is one of 48 that started in 2019, is one of 86 in phase 1, reaches primary completion later than 28 of the 87 other live ones, and was the 551st registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →57 of the 766 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–60 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Modern Research Associates, PLLC · Sites in United States
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
766 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 99 · Phase 2 218 · Phase 3 193 · Phase 4 117
First in 1977; this study’s year is marked. 48 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 77 across the 675 interventional studies, 200 across the 90 observational. Of the 645 that completed or were terminated, 378 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
526 of 766 have an industry lead sponsor. The 10 most frequent:
Wright State University is the lead sponsor of 39 studies on the registry; 13 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
Wright State University has 2 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
24 of the studies in Psoriasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05981118Phase 3Wake Forest University Health SciencesComparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) | 2027-01 |
| NCT03987763Bausch Health Americas, Inc.A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis | 2026-11 |
| NCT05570955Wake Forest University Health SciencesDeucravacitinib Adherence Study | 2026-11 |
| NCT04036188Wright State UniversityTriamcinolone With Vitamin D Synergistic Efficacy in Psoriasis | 2026-12 |
| NCT07221890Brigham and Women's HospitalA Trial of Academic Detailing to Promote Prescribing of Biosimilars | 2026-12-31 |
Add all 24 to your calendar (.ics) → With an account.
Among the 766 studies in Psoriasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
These studies are designed to assess the synergistic efficacy of topical 0.1% triamcinolone cream paired with 40,000 IU of oral vitamin D3 daily in treating mild to moderate psoriasis. The study is designed to have all subjects treated with triamcinolone cream (TAC) for 4 weeks, then will be randomized 1:1 into vitamin D3 or placebo for an additional 12 weeks. At that time, the study will become open-label and all subjects will be placed on (or continue) vitamin D3 for an additional 12 weeks. The study will take place over 28 weeks total.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm will continue to take Vitamin D3 at Week 16 to Week 28.
Drug: Triamcinolone · Dietary Supplement: Vitamin D3
Starting at Week 16, this arm will be given Vitamin D3 to take until Week 28.
Drug: Triamcinolone · Dietary Supplement: Vitamin D3 · Drug: Placebo
Triamcinolone 0.1% daily
40,000 IU Vitamin D3 daily
Placebo daily
Improvement in Psoriasis Area and Severity Score (PASI) from baseline
Subjects achieving a 50% improvement from baseline (PASI 50)
Time frame: Week 28
Improvement in Investigator Grade Assessment (IGA) from baseline
Subjects achieving a 1 point reduction from baseline
Time frame: Week 28
Improvement in Body Surface Area (BSA) from baseline
Subjects achieving a 50% reduction from baseline
Time frame: Week 28
Change in Complete Metabolic Profile Values From Baseline Due to the Combination of Topical Triamcinolone Cream and Oral Vitamin D3
Assess change through complete metabolic profile laboratory values
Time frame: Week 28
Change in Parathyroid Hormone Level Values From Baseline Due to the Combination of Topical Triamcinolone Cream and Oral Vitamin D3
Assess change through parathyroid hormone level laboratory values
Time frame: Week 28
Change in 25-Hydroxyvitamin D Values From Baseline Due to the Combination of Topical Triamcinolone Cream and Oral Vitamin D3
Assess change through 25-Hydroxyvitamin D laboratory values
Time frame: Week 28
PDFs hosted by the registry, ClinicalTrials.gov.
Started Oct 2019 (actual). Primary completion is estimated for Dec 2026, 86 months after the start.
Of 155 phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's planned 86 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triamcinolone
Wright State University